Current Report Filing (8-k)
02 Juni 2022 - 10:14PM
Edgar (US Regulatory)
0000799698
false
0000799698
2022-05-27
2022-05-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 27, 2022
CYTRX
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
|
000-15327 |
|
58-1642740 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
11726
San Vicente Boulevard, Suite 650
Los
Angeles, California 90049
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (310) 826-5648
Former
name or former address, if changed since last report: None
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(g) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights |
|
CYTR |
|
OTC
Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
May 27, 2022, in order to achieve a more equal apportionment of membership among the three director classes of the Board of Directors
(the “Board”) of CytRx Corporation (the “Company”), Joel Caldwell tendered his resignation
as a Class III director in anticipation of being appointed a Class II director. On May 27, 2022, following Mr. Caldwell’s resignation
as a Class III director, the Board reappointed Mr. Caldwell as a Class II director. Class II directors serve until the 2023 Annual Meeting
of Stockholders and Class III directors serve until the 2024 Annual Meeting of the Stockholders. The resignation and reappointment of
Mr. Caldwell was effected solely for the purpose of achieving a more equal apportionment of membership among the Board’s three
classes of directors, and for all other purposes, Mr. Caldwell’s service on the Board is deemed to have continued uninterrupted.
Mr.
Caldwell continues to serve on the Audit Committee of the Board and on the Compensation Committees of the Board. Mr. Caldwell will no
longer serve as Lead Director and will no longer receive a retainer in connection with that service to the Board. There were no other
changes to any of Mr. Caldwell’s compensation arrangements as a result of his resignation as a Class III director and reappointment
as a Class II director.
There
are no arrangements or understandings between Mr. Caldwell and any other person pursuant to which Mr. Caldwell was selected as a director.
Mr. Caldwell is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K, but may be party to
such a transaction in the future.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
CYTRX
CORPORATION |
|
|
Date:
June 2, 2022 |
/s/
John Y. Caloz |
|
John
Y. Caloz |
|
Chief
Financial Officer |
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024